Abstract
OBJECTIVES: To investigate the effects of combining nedaplatin with paclitaxel liposomes or docetaxel on survival rates and biomarkers in patients with recurrent ovarian cancer (ROC). METHODS: A retrospective analysis was carried out on the clinical data of 238 ROC patients treated at Baoji Traditional Chinese Medicine Hospital between February 2018 and February 2022. The patients were divided into a control group (n=103), which received nedaplatin combined with paclitaxel liposomes, and an observation group (n=135), receiving nedaplatin combined with docetaxel. The treatment efficacy, adverse reactions, tumor biomarkers (CA125, CEA, HE4, and AFP), and inflammatory markers (TNF-α, IL-6) before and after treatment were compared between the two groups. Patients were followed up for 2 years to observe progression-free survival (PFS), and Kaplan-Meier survival curves were plotted and Logrank tests were performed to evaluate the 2-year PFS differences. RESULTS: There were no significant differences in overall clinical efficacy or remission rates between the two groups post-treatment (both P>0.05). Both groups showed significant reductions in tumor biomarkers and inflammatory markers after treatment compared with pre-treatment levels (all P<0.05), and the differences between the groups after treatment were not significant (all P>0.05). The incidence of adverse reactions was also similar between the groups (P>0.05). Multivariate Cox regression analysis identified the treatment regimen (P<0.001), FIGO stage (P=0.005), maximum diameter of recurrent lesions (P=0.001), number of recurrent lesions (P<0.001), post-treatment CA125 (P<0.001), and post-treatment HE4 (P<0.001) as independent prognostic factors for PFS. CONCLUSIONS: The combination of nedaplatin with paclitaxel liposomes or docetaxel demonstrated comparable efficacy in ROC patients, effectively reducing tumor and inflammatory markers without increasing adverse reactions. Importantly, the combination of nedaplatin and docetaxel significantly improved PFS.